Artizan completes microbiome starter package with Brii deal, CSO hire and some money to dash for the clinic
Three years after giving a synopsis of its microbiome play with some seed funding from Malin and Hatteras Venture Partners, Artizan is raising the curtain on their first act in inflammatory bowel disease.
Armed with $12 million in total Series A cash, a partnership with China’ Brii Bio and a new CSO hire, the New Haven, CT-based biotech is ready to hunker down for some preclinical work. Meanwhile, CEO James Rosen tells me he will be getting to work raising a Series B intended to fund clinical operations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.